Medicaid May Offer Best Opportunity For Merck’s Zepatier
Newest hepatitis C entrant doesn't have the best value in all subpopulations, according to analysis by RealEndpoints, but Medicaid's mandatory discount could make up for those disadvantages.
Newest hepatitis C entrant doesn't have the best value in all subpopulations, according to analysis by RealEndpoints, but Medicaid's mandatory discount could make up for those disadvantages.